Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Lung Cancer ; (12): 591-597, 2021.
Article Dans Chinois | WPRIM | ID: wpr-888574

Résumé

In the past 20 years, with the development of molecular biology, the treatment of non-small cell lung cancer (NSCLC) has been developing. Targeted therapy has improved the survival period of patients with positive mutation of tumor driver gene. More and more targets have been found gradually. Drugs targeting different driving genes have brought the treatment of NSCLC into a promising target era. Among the many driving genes of NSCLC, the fusion of transfection proto oncogene (RET) is the addition of the epidermal growth factor receptor (EGFR), analytic lymphama kinase (ALK) and c-ros oncogene 1-receptor tyrosine kinase (ROS1) are emerging targets. Targeted drugs for RET gene fusion have been constantly updated. Recently, new high selective RET inhibitors blu-667 and loxo-292 have made important breakthroughs. This paper will review the review of the fusion mutation of RET gene in NSCLC, the detection methods, clinicopathological characteristics, targeted treatment and the research progress after drug resistance.
.

2.
Chinese Journal of Lung Cancer ; (12): 689-694, 2020.
Article Dans Chinois | WPRIM | ID: wpr-826913

Résumé

"Liquid biopsy" have been intensively studied in recent decades. The exosomes carry their maternal partial functional proteins and genes. As a form of intercellular vesicular transport, exosome-mediated intercellular communication participates in a variety of physiological and pathological processes. The information transmission mediated by exosomes is associated with pathophysiological status and plays an important role in the pathogenesis of cancer. Their detection may be beneficial for the diagnosis and treatment of tumor. This article reviews advances in knowledge on the exosome properties, the effect of exosomes on malignant tumorigenesis, and their clinical application. The data will provide a reference for clinical practitioners.

3.
Journal of Biomedical Engineering ; (6): 1325-1328, 2009.
Article Dans Chinois | WPRIM | ID: wpr-244634

Résumé

This is a research project aimed at investigating the clinical efficiency of W-F168-B, a dialyzer reprocessing machine made by Weilisheng Biological Material Company in Chengdu, evaluating its effects on total cell volume (TCV) and dialysis sufficiency, and assessing its disinfection efficacy. All subjects were randomly divided into two groups, whose dialyzers were reprocessed by W-F168-B (made in Chengdu) and RENATRON II (made by MINNTECH Company in the United States) respectively. We detected TCV of the dialyzer before and after reusing and calculated their diversity. We also calculated all subjects' Kt/V. The values of TCV diversities of two groups were 5.5 +/- 4.15 (experimental group) and 4.5 +/- 2.56 (control group) respectively, P > 0.05. The levels of Kt/V of experimental group and control group were 1.25 +/- 0.26 and 1.24 +/- 0.19, P > 0.05. T-test showed that there was no statistically significance difference between the two groups. The result of every hemoculture is negative. In conclusion, these two dialyzer reprocessing machines are similar in the effect of the dialyzer's performance and the subject's dialysis sufficiency. The reused dialyzers reprocessed by these two machines are safe for use.


Sujets)
Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Contamination de matériel , Réutilisation de matériel , Études d'évaluation comme sujet , Dialyse rénale , Sécurité , Urée , Sang
SÉLECTION CITATIONS
Détails de la recherche